Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Glaukos Corporation

< Previous 1 2 Next >
Glaukos Announces Third Quarter 2024 Financial Results
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa™, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Announces Participation in Upcoming Investor Conferences
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Announces Second Quarter 2024 Financial Results
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos to Release Second Quarter 2024 Financial Results after Market Close on July 31
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Announces Agreements to Exchange $230 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2027 for Common Stock
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Announces Participation in Upcoming Investor Conferences
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Announces First Quarter 2024 Financial Results
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Announces the Release of its 2023 Sustainability Report
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Receives Permanent J-code for iDose® TR (travoprost intracameral implant)
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos To Present Numerous Scientific Abstracts at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Announces Fourth Quarter and Full Year 2023 Financial Results
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos to Release Fourth Quarter and Full Year 2023 Financial Results after Market Close on February 21
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Net Sales and Reaffirms 2024 Revenue Guidance
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Announces Participation in the J.P. Morgan Healthcare Conference
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Announces FDA Approval of iDose® TR (travoprost intracameral implant)
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Announces Participation in Stifel Healthcare Conference
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Announces Third Quarter 2023 Financial Results
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2023 American Academy of Ophthalmology Annual Meeting
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos to Release Third Quarter 2023 Financial Results after Market Close on November 1, 2023
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Announces Participation in Wells Fargo Healthcare Conference
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Announces Second Quarter 2023 Financial Results
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Enters into a Collaboration and Marketing Agreement with Radius XR, Inc.
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos to Release Second Quarter 2023 Financial Results after Market Close on August 2, 2023
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Achieves Pipeline Milestone with Enrollment Completion in Phase 3 Confirmatory Trial for Epioxa (Epi-on)
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Announces Participation in the William Blair Growth Stock Conference
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Announces FDA Acceptance of NDA Submission for iDose TR
From Glaukos Corporation
Via Business Wire
Tickers GKOS
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.